These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 10662482

  • 1. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
    Chambers M, Hutton J, Gladman J.
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):577-93. PubMed ID: 10662482
    [Abstract] [Full Text] [Related]

  • 2. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
    Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R.
    Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
    [Abstract] [Full Text] [Related]

  • 3. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
    Greenhalgh J, Bagust A, Boland A, Martin Saborido C, Oyee J, Blundell M, Dundar Y, Dickson R, Proudlove C, Fisher M.
    Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty.
    Matchar DB, Samsa GP, Liu S.
    Value Health; 2005 Sep; 8(5):572-80. PubMed ID: 16176495
    [Abstract] [Full Text] [Related]

  • 5. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
    Shah H, Gondek K.
    Clin Ther; 2000 Mar; 22(3):362-70; discussion 360-1. PubMed ID: 10963290
    [Abstract] [Full Text] [Related]

  • 6. [Incremental cost-effectiveness of dipyridamole + acetylsalicylic acid in secondary prevention of ischemic noncardioembolic stroke].
    Claes C, Mittendorf T, Grond M, von der Schulenburg JM.
    Med Klin (Munich); 2008 Nov 15; 103(11):778-87. PubMed ID: 19165429
    [Abstract] [Full Text] [Related]

  • 7. Counting the true cost of antiplatelet therapy for stroke prevention.
    Morton JA, Newton J, Gray CS.
    Age Ageing; 2005 May 15; 34(3):212-4. PubMed ID: 15863405
    [No Abstract] [Full Text] [Related]

  • 8. Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France.
    Marissal JP, Selke B.
    Pharmacoeconomics; 2004 May 15; 22(10):661-70. PubMed ID: 15244491
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack.
    Sarasin FP, Gaspoz JM, Bounameaux H.
    Arch Intern Med; 2000 Oct 09; 160(18):2773-8. PubMed ID: 11025787
    [Abstract] [Full Text] [Related]

  • 10. Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness.
    Rothlisberger JM, Ovbiagele B.
    J Comp Eff Res; 2015 Aug 09; 4(4):377-84. PubMed ID: 26274799
    [Abstract] [Full Text] [Related]

  • 11. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G, Fragoulakis V, Maniadakis N.
    Appl Health Econ Health Policy; 2012 Jul 01; 10(4):261-71. PubMed ID: 22667992
    [Abstract] [Full Text] [Related]

  • 12. Aggrenox: an aspirin and extended-release dipyridamole combination.
    Wong NN.
    Heart Dis; 2001 Jul 01; 3(5):340-6. PubMed ID: 11975816
    [Abstract] [Full Text] [Related]

  • 13. [An acetylsalicylic acid-dypiridamole combination (Asasantine) in the prevention of the recurrence of cerebrovascular accidents (a cost-effectiveness analysis)].
    Kurz X, Annemans L, Dresse A.
    Rev Med Liege; 1998 May 01; 53(5):265-9. PubMed ID: 9689880
    [Abstract] [Full Text] [Related]

  • 14. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
    Logman JF, Heeg BM, Herlitz J, van Hout BA.
    Appl Health Econ Health Policy; 2010 May 01; 8(4):251-65. PubMed ID: 20578780
    [Abstract] [Full Text] [Related]

  • 15. Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke.
    Redman AR, Ryan GJ.
    Expert Opin Pharmacother; 2004 Jan 01; 5(1):117-23. PubMed ID: 14680441
    [Abstract] [Full Text] [Related]

  • 16. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
    Kirshner HS.
    Int J Clin Pract; 2007 Oct 01; 61(10):1739-48. PubMed ID: 17877660
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft.
    Nee R, Parker AL, Little DJ, Yuan CM, Himmelfarb J, Lowe SR, Abbott KC.
    Clin Nephrol; 2014 Jan 01; 81(1):38-51. PubMed ID: 24161074
    [Abstract] [Full Text] [Related]

  • 18. Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective.
    Heeg B, Damen J, Van Hout B.
    Pharmacoeconomics; 2007 Jan 01; 25(12):1063-82. PubMed ID: 18047390
    [Abstract] [Full Text] [Related]

  • 19. Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK.
    Karnon J, Brennan A, Pandor A, Fowkes G, Lee A, Gray D, Coshall C, Nicholls C, Akehurst R.
    Curr Med Res Opin; 2005 Jan 01; 21(1):101-12. PubMed ID: 15881481
    [Abstract] [Full Text] [Related]

  • 20. Aggrenox: a fixed-dose combination of aspirin and dipyridamole.
    Lenz TL, Hilleman DE.
    Ann Pharmacother; 2000 Nov 01; 34(11):1283-90. PubMed ID: 11098344
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.